e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcellx, Inc. - Common Stock
(NQ:
ACLX
)
75.54
+0.33 (+0.44%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcellx, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
In-Depth Examination Of 14 Analyst Recommendations For Arcellx
December 09, 2024
Via
Benzinga
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
December 09, 2024
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Via
Investor's Business Daily
14 Analysts Have This To Say About Arcellx
December 09, 2024
Via
Benzinga
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
December 09, 2024
Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes.
Via
Benzinga
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
December 08, 2024
From
Arcellx, Inc.
Via
Business Wire
Analyst Expectations For Arcellx's Future
November 08, 2024
Via
Benzinga
Navigating 7 Analyst Ratings For Arcellx
November 06, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Arcellx
October 22, 2024
Via
Benzinga
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
November 07, 2024
From
Arcellx, Inc.
Via
Business Wire
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
November 06, 2024
Via
Benzinga
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
November 05, 2024
From
Arcellx, Inc.
Via
Business Wire
4 Analysts Assess Arcellx: What You Need To Know
October 18, 2024
Via
Benzinga
Assessing Arcellx: Insights From 7 Financial Analysts
August 09, 2024
Via
Benzinga
Decoding 8 Analyst Evaluations For Arcellx
July 22, 2024
Via
Benzinga
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024
August 09, 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
August 08, 2024
From
Arcellx, Inc.
Via
Business Wire
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.
Via
InvestorPlace
Exposures
Product Safety
Arcellx Stock Earns Relative Strength Rating Upgrade
June 21, 2024
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.
Via
Investor's Business Daily
The Latest Analyst Ratings For Arcellx
June 18, 2024
Via
Benzinga
Expert Ratings For Arcellx
May 31, 2024
Via
Benzinga
Analyst Expectations For Arcellx's Future
May 14, 2024
Via
Benzinga
Peering Into Arcellx's Recent Short Interest
April 15, 2024
Via
Benzinga
7 Biotech Stocks to Put on Your Breakthrough Radar
May 27, 2024
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.
Via
InvestorPlace
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 09, 2024
From
Arcellx, Inc.
Via
Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 09, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Arcellx Provides First Quarter 2024 Financial Results
May 09, 2024
From
Arcellx, Inc.
Via
Business Wire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
May 09, 2024
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.
Via
InvestorPlace
Arcellx to Participate in Two Upcoming Investor Conferences
May 07, 2024
From
Arcellx, Inc.
Via
Business Wire
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Arcellx, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
wpDiscuz
Insert
